OUR PIPELINE & SCIENCE

We are advancing a diverse pipeline of novel small molecule candidates, each derived from a deep understanding of the molecular drivers of disease and enabled by our unique expertise in computational chemistry and drug discovery.

TARGETs

  • DISCOVERY
  • PRECLINICAL
  • CLINICAL
TYK2 (Catalytic)

Autoimmune, Oncology

Autoimmune, Oncology

PRECLINICAL
TYK2 (Allosteric)

Autoimmune

DISCOVERY
Sting Agonist

Immuno-oncology

DISCOVERY
Sting Antagonist

Autoimmune

DISCOVERY
other

Undisclosed (Metabolic, Oncology, Immunology)

Undisclosed
(Metabolic, Oncology, Immunology)

DISCOVERY

partnered programs

ACC

Metabolic, Oncology, Immunology

ACC

In May 2016, Gilead Sciences Inc. acquired Nimbus Apollo, Inc., a wholly owned subsidiary of Nimbus, and its Acetyl-CoA Carboxylase (ACC) inhibitor program for an upfront payment of $400 million. This program includes the lead candidate, NDI-010976, an allosteric ACC inhibitor, and other preclinical ACC inhibitors for the treatment of non-alcoholic steatohepatitis (NASH), and for the potential treatment of hepatocellular carcinoma (HCC) and other diseases. We have realized half of the total $1.2 billion deal value, when we subsequently received a $200 million payment in November 2016 – the first of several potential additional development-related payments that could total up to $800 million. Gilead is responsible for development and commercialization of our original molecule and other ACC inhibitors.

CLINICAL
IRAK4

Immunology, Oncology

IRAK4

In October 2015, we announced an exclusive worldwide license agreement with Genentech, a member of the Roche Group, to discover and develop small molecule inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4). Genentech is responsible for all preclinical and clinical development, manufacturing and commercialization.

PRECLINICAL
Undisclosed(Montsanto)

Broad-spectrum fungicides

Undisclosed (Anti-fungal)

We work in collaboration with Monsanto to develop broad-spectrum fungicides with new modes of action to help farmers control diseases and promote overall plant health. With Monsanto, we created a jointly owned entity in 2013, which uses access to Nimbus’ validated computational platform to develop new fungicides.

CLINICAL
ACC

In May 2016, Gilead Sciences Inc. acquired Nimbus Apollo, Inc., a wholly owned subsidiary of Nimbus, and its Acetyl-CoA Carboxylase (ACC) inhibitor program for an upfront payment of $400 million. This program includes the lead candidate, NDI-010976, an allosteric ACC inhibitor, and other preclinical ACC inhibitors for the treatment of non-alcoholic steatohepatitis (NASH), and for the potential treatment of hepatocellular carcinoma (HCC) and other diseases. We have realized half of the total $1.2 billion deal value, when we subsequently received a $200 million payment in November 2016 – the first of several potential additional development-related payments that could total up to $800 million. Gilead is responsible for development and commercialization of our original molecule and other ACC inhibitors.

IRAK4

In October 2015, we announced an exclusive worldwide license agreement with Genentech, a member of the Roche Group, to discover and develop small molecule inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4). Genentech is responsible for all preclinical and clinical development, manufacturing and commercialization.

Undisclosed (Anti-fungal)

We work in collaboration with Monsanto to develop broad-spectrum fungicides with new modes of action to help farmers control diseases and promote overall plant health. With Monsanto, we created a jointly owned entity in 2013, which uses access to Nimbus’ validated computational platform to develop new fungicides.

Publications & Abstracts

Publications
posters & abstracts

location

784 Memorial Drive, Suite 100
Cambridge, MA 02139
USA

call US

857-999-2009